Literature DB >> 16394599

Influence of interferon therapy on signal-averaged and ambulatory electrocardiograms in patients with chronic active hepatitis.

Shin-ichi Hiramatsu1, Toru Maruyama, Hiroyuki Ito, Shinji Shimoda, Yoshikazu Kaji, Mine Harada.   

Abstract

Although interferon (IFN) shows cardiotoxicity and arrhythmogenesis, the influence of IFN on signal-averaged electrocardiography remains to be clarified. The aim of this study was to test a clinical hypothesis that IFN therapy for hepatitis C virus may induce ventricular late potentials (LPs) and related arrhythmias in patients with chronic active hepatitis. Signal-averaged and ambulatory electrocardiograms were recorded sequentially in patients with chronic active hepatitis C (n = 22) throughout the entire period of IFN therapy. The filtered QRS duration (fQRS) and low amplitude (< 40 microV) signal duration (LAS40) were significantly increased (95.5 +/- 8.5 to 99.6 +/- 9.4 msec, P < 0.0001, and 32.8 +/- 3.1 to 36.3 +/- 3.0 msec, P < 0.0001, respectively), whereas the root mean square voltage in the terminal 40 msec of the fQRS (RMS40) was significantly decreased (25.5 +/- 5.4 to 22.3 +/- 5.2 microV, P < 0.005) 1 month after starting the IFN therapy. The ventricular LP was negative in all subjects before starting therapy, but became positive in 7 patients after the therapy commenced. There were no differences in clinical baseline characteristics between the LP-positive (n = 7) and LP-negative (n = 15) groups. Significant increases in mean heart rate, fQRS, and LAS40 were observed after starting the therapy, irrespective of the appearance of the ventricular LP, whereas a decrease in RMS40 was observed only in the LP-positive group. No sustained ventricular arrhythmias were documented in the ambulatory electrocardiography and no cardiac events were encountered in the follow-up period. Therefore, the results indicate a reversible and subclinical risk of IFN-induced arrhythmogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16394599     DOI: 10.1536/ihj.46.1033

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  3 in total

1.  Cardiovascular risk assessment by electrocardiographic Holter monitoring in patients with chronic hepatitis C.

Authors:  Adam R Poliwczak; Jolanta Białkowska; Joanna Woźny; Marzena Koziróg; Agnieszka Bała; Maciej Jabłkowski
Journal:  Arch Med Sci       Date:  2020-07-15       Impact factor: 3.318

Review 2.  Treatment of hepatitis C virus infection and associated vascular complications: a literature review.

Authors:  Reza Karbasi-Afshar
Journal:  Iran J Med Sci       Date:  2014-05

3.  Is combination therapy for chronic hepatitis C toxic for cardiac function?

Authors:  Ramzy Almawardy; Walid Elhammady; Nasser Mousa; Sherif Abotaleb
Journal:  Hepat Mon       Date:  2012-08-20       Impact factor: 0.660

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.